Horizon Therapeutics: New Long-Term Data for UPLIZNA (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics: New Long-Term Data for UPLIZNA (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) -- UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP) -- -- Results from NMOSD patient survey describe long and daunting journey to diagnosis -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurology's 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the ...
Source: finanznachrichten.de